# Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

> **NCT05623319** · PHASE2 · RECRUITING · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 60 (estimated)

## Conditions studied

- SCLC,Extensive Stage

## Interventions

- **DRUG:** Pembrolizumab/Olaparib

## Key facts

- **NCT ID:** NCT05623319
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-27
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623319, "Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05623319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*